Article Information
History
- March 26, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ester Lopez1,
- Ebene R. Haycroft1,
- Amy Adair2,
- Francesca L. Mordant1,
- Matthew T. O’Neill2,
- Phillip Pymm2,3,
- Samuel Redmond1,
- Nicholas A. Gherardin1,6,
- Adam K. Wheatley1,3,
- Jennifer. A. Juno1,
- Kevin J. Selva1,
- Samantha Davis1,
- Leigh Harty1,
- Damian F.J. Purcell1,
- Kanta Subbarao1,5,
- Dale I. Godfrey1,6,
- Stephen J. Kent1,
- Wai-Hong Tham2,4 and
- Amy W. Chung1,*
- 1Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia
- 2The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia
- 3Australian Research Council Centre for Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Parkville, Victoria, Australia
- 4Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia
- 5WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia
- 6Australian Research Council Centre of Excellence for Advanced Molecular Imaging, University of Melbourne, Melbourne, Victoria, Australia
- ↵*Correspondence:
Amy W Chung, Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Victoria 3000, Australia, +61 3 8344 1717, awchung{at}unimelb.edu.au
Posted March 26, 2021.
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay
